MX2022014909A - Tratamiento del cáncer. - Google Patents
Tratamiento del cáncer.Info
- Publication number
- MX2022014909A MX2022014909A MX2022014909A MX2022014909A MX2022014909A MX 2022014909 A MX2022014909 A MX 2022014909A MX 2022014909 A MX2022014909 A MX 2022014909A MX 2022014909 A MX2022014909 A MX 2022014909A MX 2022014909 A MX2022014909 A MX 2022014909A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- breast cancer
- subject
- chemotherapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 102000017578 LAG3 Human genes 0.000 abstract 1
- 101150030213 Lag3 gene Proteins 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 abstract 1
- 208000026534 luminal B breast carcinoma Diseases 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008037.0A GB202008037D0 (en) | 2020-05-28 | 2020-05-28 | Treatment of cancer |
| RU2020131384A RU2020131384A (ru) | 2020-05-28 | 2020-09-23 | Лечение рака |
| GBGB2018062.6A GB202018062D0 (en) | 2020-11-17 | 2020-11-17 | Treatment of cancer |
| PCT/EP2021/057588 WO2021239292A1 (en) | 2020-05-28 | 2021-03-24 | Treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014909A true MX2022014909A (es) | 2023-03-06 |
Family
ID=75362569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014909A MX2022014909A (es) | 2020-05-28 | 2021-03-24 | Tratamiento del cáncer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230210946A1 (https=) |
| EP (1) | EP4157313A1 (https=) |
| JP (1) | JP2023527209A (https=) |
| KR (1) | KR20230028321A (https=) |
| CN (1) | CN116133674A (https=) |
| AU (1) | AU2021280214A1 (https=) |
| BR (1) | BR112022024179A2 (https=) |
| CA (1) | CA3184309A1 (https=) |
| IL (1) | IL298507A (https=) |
| MX (1) | MX2022014909A (https=) |
| WO (1) | WO2021239292A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4475955A1 (en) * | 2022-02-11 | 2024-12-18 | Immutep S.A.S. | Treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| GB201322626D0 (en) * | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| GB201500374D0 (en) * | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| JP2021534177A (ja) * | 2018-08-16 | 2021-12-09 | ジー１ セラピューティクス， インコーポレイテッド | 医学的障害を治療するためのベンゾチオフェンエストロゲン受容体モジュレーター |
| WO2020047329A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
-
2021
- 2021-03-24 IL IL298507A patent/IL298507A/en unknown
- 2021-03-24 BR BR112022024179A patent/BR112022024179A2/pt unknown
- 2021-03-24 MX MX2022014909A patent/MX2022014909A/es unknown
- 2021-03-24 CA CA3184309A patent/CA3184309A1/en active Pending
- 2021-03-24 WO PCT/EP2021/057588 patent/WO2021239292A1/en not_active Ceased
- 2021-03-24 JP JP2022573285A patent/JP2023527209A/ja active Pending
- 2021-03-24 US US17/928,048 patent/US20230210946A1/en active Pending
- 2021-03-24 KR KR1020227046217A patent/KR20230028321A/ko active Pending
- 2021-03-24 AU AU2021280214A patent/AU2021280214A1/en active Pending
- 2021-03-24 CN CN202180059063.2A patent/CN116133674A/zh active Pending
- 2021-03-24 EP EP21716087.8A patent/EP4157313A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230028321A (ko) | 2023-02-28 |
| JP2023527209A (ja) | 2023-06-27 |
| US20230210946A1 (en) | 2023-07-06 |
| IL298507A (en) | 2023-01-01 |
| AU2021280214A1 (en) | 2023-02-02 |
| EP4157313A1 (en) | 2023-04-05 |
| CA3184309A1 (en) | 2021-12-02 |
| CN116133674A (zh) | 2023-05-16 |
| BR112022024179A2 (pt) | 2023-02-07 |
| WO2021239292A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551513A1 (en) | Sos1 inhibitors | |
| MX2023013085A (es) | Inhibidores de ras. | |
| MX2024015215A (es) | Inhibidores macrociclicos de ras | |
| PH12021552856A1 (en) | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
| PH12021550620A1 (en) | Ophthalmic composition for treatment of dry eye disease | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MX2023012447A (es) | Ergolinas novedosas y metodos para tratar los desordenes del humor. | |
| MX2021005646A (es) | Métodos de tratamiento de cáncer con agentes de unión a tubulina. | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| ZA202201437B (en) | Compositions and methods for treating inflammasome related diseases or conditions | |
| TN2010000204A1 (en) | Kinesin inhibitors as cancer therapeutics | |
| MX2021008712A (es) | Derivados heterociclicos. | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 | |
| MX2025002424A (es) | Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer | |
| MX2025013117A (es) | Ergolinas novedosas y métodos de tratamiento de trastornos del estado de ánimo | |
| MX2022014909A (es) | Tratamiento del cáncer. | |
| WO2023114847A3 (en) | Compositions and methods for treating disease | |
| WO2021056025A3 (en) | Anti-epha10 antibodies and methods of use thereof |